Search
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalOn June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. … It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body.
Fluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalIt was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigational[L34319] The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but are more sensitive and can reveal cancerous tissue in any area of the body provided … It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.
Natamycin
go.drugbank.com/drugs/DB00826ApprovedInvestigationalAmphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
Chlorpromazine
go.drugbank.com/drugs/DB00477ApprovedInvestigationalVet approvedLike the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors.
Bortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigational[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.
Dolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigational[A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013.
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. … It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.
Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A227963] Approved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic
Cefepime
go.drugbank.com/drugs/DB01413ApprovedInvestigational[A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical